On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Investigational; FDA has identified safety-information and peptide-quality concerns for compounded use.
Upstream reproductive signalling
Kisspeptin-10 acts upstream of pituitary gonadotropin release; the male studies demonstrate stimulation of LH secretion. [1]
What the evidence shows
Hormone response in men
A 2011 study used very small groups of healthy men and found increased luteinizing hormone secretion and testosterone responses to kisspeptin-10. The study measured endocrine physiology, not pregnancies, sustained symptom relief or sexual satisfaction. [1]
Response depends on context
Another 2011 study found different gonadotropin responses in men and women at different menstrual-cycle stages. This argues against assuming a uniform response across people, reproductive conditions or hormone backgrounds. [2]
What remains unknown
The relation between short-term hormone changes and meaningful clinical benefit is unresolved. These studies cannot validate routine use during testosterone therapy or a fertility guarantee.
Safety
Immune reactions and purity
FDA notes possible immunogenicity, peptide-related impurities and insufficient safety information for proposed routes. [3]
Small samples cannot establish broad safety
Short physiological experiments are not powered to detect uncommon events, pregnancy effects or consequences of prolonged exposure. [2]
The research preparation matters
Experimental administration and commercial compounded products can differ in purity, stability and exposure. The cited trials are not product-equivalence studies. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is kisspeptin-54 research evidence for kisspeptin-10?
They are different peptide lengths. A study must be checked for the exact molecule and preparation.
Would a higher LH result prove fertility improved?
No. Hormonal responses, semen measures, ovulation, pregnancy and live birth are different outcomes.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- George et al.: kisspeptin-10 endocrine responseJournal of Clinical Endocrinology and Metabolism, 2011; small healthy-male physiological studies.
- Jayasena et al.: sex and cycle-stage response to kisspeptin-10Journal of Clinical Endocrinology and Metabolism, 2011; small male and female experimental groups.
- FDA: peptide bulk-substance safety concernsFDA identifies route-specific immunogenicity, characterization and evidence gaps; withdrawn nominations are listed separately from current category 2.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.